Skip to main content
Xiangxue Pharmaceutical Co., Ltd. logo

Xiangxue Pharmaceutical Co., Ltd. — Investor Relations & Filings

Ticker · 300147 ISIN · CNE100000Y92 LEI · 3003000D8UMO4KQ95B57 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,280 across all filing types
Latest filing 2025-04-21 Declaration of Voting R…
Country CN China
Listing Shenzhen Stock Exchange 300147

About Xiangxue Pharmaceutical Co., Ltd.

https://www.xphcn.com

Xiangxue Pharmaceutical Co., Ltd. specializes in the research, development, manufacturing, and distribution of modern Traditional Chinese Medicine (TCM), chemical drugs, and biological products. The company is recognized for its focus on the modernization of TCM, utilizing advanced technology to standardize and enhance traditional formulas. Its flagship products include anti-viral oral liquids and Banlan'gen granules, which are widely used for respiratory health. Beyond traditional treatments, the company has expanded into high-tech biomedical fields, including precision medicine and adoptive cell therapy, specifically TCR-T cell technology for cancer treatment. Xiangxue operates a comprehensive value chain encompassing medicinal herb cultivation, pharmaceutical manufacturing, and healthcare services. By integrating digital technology with pharmaceutical expertise, the company aims to provide integrated health solutions and innovative therapies.

Recent filings

Filing Released Lang Actions
2025年第一次临时股东会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a detailed announcement of the resolutions passed at the 2025 first extraordinary general meeting (临时股东会) of 广州市香雪制药股份有限公司. It includes information about the meeting date, voting methods, attendance, voting results, and legal opinions confirming the validity of the meeting and resolutions. The content focuses on the official results of shareholder votes on specific proposals. There is no indication that this is a full annual or interim report, audit report, or other financial report. The document is not a mere notice of a report publication but a formal announcement of voting results from a shareholder meeting. Therefore, the document fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA). The document length is 2125 characters, which is consistent with a detailed voting results announcement rather than a full report.
2025-04-21 Chinese
关于临时管理人公开选聘审计、评估及财务顾问机构的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by Guangzhou Xiangxue Pharmaceutical Co., Ltd. regarding the open selection of audit, evaluation, and financial advisory institutions by the temporary administrator during a pre-restructuring process. It includes detailed information about the selection criteria, scope of work, submission requirements, and procedures for these intermediary institutions. The document is not a financial report, earnings release, or management discussion but rather a regulatory announcement related to the restructuring process and the engagement of professional service providers. It does not contain financial statements or detailed financial analysis but is a formal disclosure about the selection process and related legal and procedural information. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2025-04-18 Chinese
关于公司预先开展债权申报工作通知的公告
Legal Proceedings Report Classification · 95% confidence The document is a public announcement by Guangzhou Xiangxue Pharmaceutical Co., Ltd. regarding the initiation of a debt claim filing process during a pre-restructuring phase ordered by the Guangzhou Intermediate People's Court. It includes details about the court decision, the appointment of temporary administrators, instructions for creditors to file claims, and risk warnings related to the restructuring and potential delisting risks. The document is a formal notice about a legal and financial process affecting the company, but it does not contain financial statements, audit results, or detailed financial performance data. It is not a full report like an Annual Report (10-K) or Interim Report (IR), nor is it a certification or a voting result announcement. It is a regulatory announcement related to legal proceedings and restructuring. Therefore, the most appropriate classification is Legal Proceedings Report (LTR). The document length is 2329 characters, which is consistent with an announcement rather than a full report.
2025-04-16 Chinese
关于广州中院同意公司预重整并指定临时管理人的公告
Regulatory Filings Classification · 95% confidence The document is an official announcement from Guangzhou Xiangxue Pharmaceutical Co., Ltd. regarding the Guangzhou Intermediate People's Court's decision to approve the company's pre-restructuring and appoint a temporary administrator. It details the legal and procedural status of the company's pre-restructuring process, risks involved, and regulatory compliance. The document is a formal public disclosure about a legal and financial restructuring event, not a full financial report, earnings release, or management discussion. It is not a report publication announcement since it contains substantive information about the court decision and company status. The document fits best into the category of Regulatory Filings (RNS) as it is a regulatory announcement about a significant legal and financial event affecting the company, without being a full audit report, annual report, or other specific report type.
2025-04-13 Chinese
关于控股股东资金占用形成的债权与应付控股股东的债务进行冲抵的专项审核报告
Audit Report / Information Classification · 95% confidence The document is a specialized audit report issued by Beijing Dehao International Certified Public Accountants regarding the offsetting of debts and receivables between the controlling shareholder and the company, Guangzhou Xiangxue Pharmaceutical Co., Ltd. It includes detailed financial data, audit procedures, and conclusions about the offsetting of shareholder funds and equity transfer payments as of March 24, 2025. The document is titled as a "专项审核报告" (special audit report) and contains audit findings, responsibilities of management and auditors, and detailed financial tables. It is not a full annual or interim report, nor is it a simple announcement or certification. It fits the definition of an Audit Report / Information (AR) as it is a standalone audit report focusing on a specific financial matter, with detailed audit results and accounting principles applied. The document length is 4212 characters, which is sufficient for a detailed audit report but not a brief announcement. Therefore, the correct classification is AR with high confidence. Q1 2025
2025-04-03 Chinese
以资抵债方案之独立财务顾问报告
Capital/Financing Update Classification · 95% confidence The document is titled as an "Independent Financial Advisor Report" related to a debt-to-equity swap plan involving Guangzhou Xiangxue Pharmaceutical Co., Ltd. It contains detailed financial and legal analysis, audit references, and compliance with regulatory guidelines, specifically referencing the China Securities Regulatory Commission and related regulatory instructions. The document includes audit and asset evaluation reports, board meeting resolutions, and detailed financial data about the transaction. It is a comprehensive advisory report prepared by an independent financial advisor for a specific financing and debt restructuring transaction. This type of document is not a general annual or interim report, nor is it a simple announcement or certification. It is a detailed financial advisory report related to a capital restructuring transaction involving asset offset against debt. Therefore, the document fits best into the category of Capital/Financing Update (CAP). The document length (7202 characters) and content depth support this classification with high confidence.
2025-04-03 Chinese

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.